BCLSI
THRD

Bain Capital Life Sciences Investors’s Third Harmonic Bio THRD Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-640,631
Closed -$3.08M – 32
2023
Q2 		$3.08M Hold
640,631
– – 0.32% 29
2023
Q1 		$2.64M Sell
640,631
-511,026
-44% -$2.17M 0.33% 30
2022
Q4 		$4.95M Sell
1,151,657
-1,128,425
-49% -$18.9M 0.55% 28
2022
Q3 		$43.3M Buy
+2,280,082
New +$41.1M 5.16% 8

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bain Capital Life Sciences Investors's THRD Position: Q3 2023 in Review

Bain Capital Life Sciences Investors sold out of Third Harmonic Bio (THRD) in Q3 2023, closing a stake of 640,631 shares — an estimated $3.08M sold.

Bain Capital Life Sciences Investors first reported a position in THRD in Q3 2022 and held it in 4 quarters. The position peaked at $43.3M in Q3 2022. 56 funds tracked by Wall St. Rank hold THRD as of Q3 2023.

  • Bain Capital Life Sciences Investors reported no remaining Third Harmonic Bio position as of Q3 2023 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 640,631 Third Harmonic Bio shares in Q3 2023, an estimated $3.08M.
  • Bain Capital Life Sciences Investors first reported a position in Third Harmonic Bio in Q3 2022 and held it in 4 quarters.
  • Bain Capital Life Sciences Investors's Third Harmonic Bio position peaked at $43.3M in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2023, filed 14 Nov 2023.